Interferon beta-1a

Generic Name: Interferon beta-1a

Brand Names: Avonex, Rebif

Drug Type: Biotech

CAS Number: 145258-61-3

Unique Ingredient Identifier: XRO4566Q4R

Background: Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.

Indication: For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Associated Conditions: Relapsing Multiple Sclerosis (RMS)

Clinical Trials

Early Interferon-beta Treatment for West-Nile Virus Infection

Phase 2

Recruiting

Conditions: West Nile Fever Myelitis
West Nile Virus
West Nile Fever Encephalitis
West Nile Fever With Other Complications

Interventions: Drug: Saline
Drug: Rebif 44 MCG Per 0.5 ML Prefilled Syringe

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-23

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 100

Registration Number: NCT06510426

Locations: 🇮🇱
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden

Active, not recruiting

Conditions: Multiple Sclerosis (MS)

Interventions: Drug: Avonex (IFNβ-1-a, Biogen Netherlands B.V)
Drug: Rebif (IFNβ-1-a, Merck Europe B.V.)
Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited)
Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)
Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)
Drug: MS disease modifying drugs (MSDMDs)

First Posted Date: 2023-09-26

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 4

Registration Number: NCT06053749

Locations: 🇸🇪
Many locations, Multiple Locations, Sweden

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma
Nasopharyngeal Cancer
Nasopharynx Cancer
Nasopharyngeal Neoplasms

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: 5-Fluorouracil
Drug: Gemcitabine
Radiation: Radiotherapy
Drug: Interferon beta-1a
Procedure: MRI
Procedure: PET
Behavioral: Patient-Reported Outcomes

First Posted Date: 2023-08-31

Last Posted Date: 2024-05-16

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 57

Registration Number: NCT06019130

Locations: 🇩🇪
Department of Pediatric Oncology and Hematology, Charité University Medicine Berlin, Berlin, Germany
🇩🇪
Uniklinik RWTH Aachen, Department of Internal Medicine, Aachen, Germany
🇩🇪
Evangelisches Klinikum Bethel, Children's Hospital, Bielefeld, Germany

and more 28 locations

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Avonex
Drug: Diroximel Fumarate
Drug: Dimethyl Fumarate
Biological: Tysabri

First Posted Date: 2022-12-20

Last Posted Date: 2024-06-24

Lead Sponsor: Biogen

Target Recruit Count: 908

Registration Number: NCT05658497

Locations: 🇨🇭
Inselspital, Bern, Switzerland
🇺🇸
IQVIA US Office, Durham, North Carolina, United States
🇮🇪
St Vincent's University Hospital, Dublin, Ireland

and more 2 locations

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Phase 2

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: MetFORMIN 1000 Mg Oral Tablet
Drug: Interferon beta-1a

First Posted Date: 2022-03-28

Last Posted Date: 2023-03-20

Lead Sponsor: German University in Cairo

Target Recruit Count: 80

Registration Number: NCT05298670

Locations: 🇪🇬
Nasser Institute for Research and Treatment, Cairo, Egypt

Public Health Emergency: SOLIDARITY TRIAL Philippines

Not Applicable

Completed

Conditions: Covid19

Interventions: Drug: Remdesivir
Drug: Lopinavir / Ritonavir
Drug: Hydroxychloroquine
Drug: Acalabrutinib
Drug: Interferon beta-1a

First Posted Date: 2021-08-27

Last Posted Date: 2022-03-02

Lead Sponsor: University of the Philippines

Target Recruit Count: 1314

Registration Number: NCT05024006

Locations: 🇵🇭
Chinese General Hospital, Manila, Metro Manila, Philippines
🇵🇭
UP - Philippine General Hospital, Manila, Metro Manila, Philippines
🇵🇭
San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines

and more 22 locations

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

Phase 3

Completed

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19

Interventions: Drug: Placebo
Drug: SNG001

First Posted Date: 2021-02-01

Last Posted Date: 2023-03-27

Lead Sponsor: Synairgen Research Ltd.

Target Recruit Count: 623

Registration Number: NCT04732949

Locations: 🇧🇷
Instituto Mederi de Pesquisa e Saúde, Passo Fundo, Rio Grande Do Sul, Brazil
🇲🇽
Hospital General de Culiacan D, Culiacan, Sinaloa, Mexico
🇲🇽
Hospital General Regional O´Hu, Merida, Yucatán, Mexico

and more 109 locations

World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments

Phase 3

Conditions: Covid19

Interventions: Other: Standard of Care
Drug: Acalabrutinib
Drug: Remdesivir
Drug: Interferon beta-1a

First Posted Date: 2020-12-01

Last Posted Date: 2021-05-13

Lead Sponsor: The University of The West Indies

Target Recruit Count: 100

Registration Number: NCT04647669

Locations: 🇯🇲
Univeristy of the West Indies, Kingston, Jamaica

ACTIV-2: A Study for Outpatients With COVID-19

Phase 2

Completed

Conditions: Coronavirus
Covid19

Interventions: Biological: bamlanivimab 7000mg
Drug: Placebo for Bamlanivimab 7000mg
Biological: bamlanivimab 700mg
Drug: Placebo for Bamlanivimab 700mg
Biological: BRII-196+BRII-198
Drug: Placebo for BRII-196+BRII-198
Biological: AZD7442 (IV)
Biological: AZD7442 (IM)
Drug: Placebo for SNG001
Drug: Placebo for Camostat
Biological: SAB-185 (3,840 Units/kg)
Drug: Placebo for SAB-185 (low dose)
Biological: SAB-185 (10,240 Units/kg)
Drug: Placebo for SAB-185 (high dose)
Biological: BMS-986414 + BMS-986413
Drug: Placebo for BMS-986414 + BMS-986413
Drug: CASIRIVIMAB + IMDEVIMAB
Drug: Placebo for AZD7442 (IV)
Drug: Placebo for AZD7442 (IM)
Drug: SNG001
Drug: Camostat

First Posted Date: 2020-08-19

Last Posted Date: 2024-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4044

Registration Number: NCT04518410

Locations: 🇺🇸
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States
🇺🇸
Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States

and more 249 locations

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Phase 3

Completed

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Interferon beta-1a
Drug: Remdesivir

First Posted Date: 2020-07-30

Last Posted Date: 2022-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 969

Registration Number: NCT04492475

Locations: 🇺🇸
Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States
🇺🇸
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States

and more 61 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy